Starton Therapeutics Files PCT & US Patent Application for Continuous Delivery of Lenalidomide & Class of Immunomodulatory Agents

Starton Therapeutics Inc. recently announced it has filed PCT (Patent Cooperation Treaty) and US Non-Provisional patent applications entitled Continuous Delivery of Lenalidomide and Other Immunomodulatory Agents on April 21, 2020 (PCT Application No. PCT/US20/29159 and US Application No. 16/854,810).

The PCT application, filed with the PCT receiving office at the US Patent & Trademark Office, allows Starton to file patent applications to seek protection for the methods disclosed therein in most major market countries throughout the world. The US non-provisional patent application was filed with the US Patent and Trademark Office and, like the PCT application, relates to Starton’s technologies for methods of treatment with immunomodulatory compounds.  The US non-provisional patent application and any national stage applications based on the PCT application that are filed, if granted, have the potential to give 20 years of patent protection for the methods – until at least 2040.

Pedro Lichtinger, Starton Chairman and Chief Executive Officer, said “The technology embodied in this patent family will allow us to proceed with our planned first in human continuous delivery study in patients towards the end of this year. We believe that the technology, if replicated in the clinic, will provide a best in class, breakthrough product for hematological malignancies that can significantly improve patient outcomes.”

Jamie Oliver, PhD, Starton Chief Medical Officer and inventor, added “The filing protects our invention of continuous delivery of lenalidomide and other immunomodulatory (imid) agents. We believe that the invention may have broad applications beyond multiple myeloma to include hematologic malignancies, mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), lymphomas, as well as solid tumor cancers or inflammatory diseases.”

The STAR-LLD program includes development of two continuous delivery formulations – a subcutaneous (SC) ambulatory pump and a multi-day transdermal formulation. The SC ambulatory pump program is currently engaging with contract manufacturers for a Phase 1 efficacy and safety study currently planned for treatment of late-stage chronic lymphocytic leukemia (CLL) patients. The open-label study is expected to provide initial efficacy and safety readouts within the next 18 months.

The STAR-LLD program has already displayed unprecedented efficacy results in a murine multiple myeloma model. The STAR-LLD continuous infusion displayed superior efficacy versus lenalidomide standard of care: tumor volume increase at day 29 was 483% with standard of care versus an -81% reduction in tumor volume in the STAR-LLD group. Progression-free survival was also significantly increased in the continuous infusion group, STAR-LLD had the longest survival with two animals surviving to 100 days, where all animals treated with lenalidomide standard of care had failed treatment by day 52.

About Starton Therapeutics
Clinical-stage biotechnology company focused on transforming standard of care therapeutics. Starton uses proven transdermal technology with proprietary drivers to obtain new indications or develop on-label superiority for patients with hematological malignancies. To learn more, visit www.startontx.com.